Something in need is something indeed -- EGFR-TKIs in EGFR-mutated lung cancer: Setting the new standard for 1st line therapy -- Advances on EGFR mutation for lung cancer -- Angiogenesis in cancer: Anti-VEGF escape mechanisms -- Statistical considerations and endpoints for clinical lung cancer studies: Can progression free survival (PFS) substitute overall survival (OS) as a valid endpoint in clinical trials for advanced non-small-cell lung cancer? -- Circulating soluble intercellular adhesion molecule-1 in lung cancer: a systematic review -- Are three doses of stereotactic ablative radiotherapy (SABR) more effective than 30 doses of conventional radiotherapy? -- Cetuximab in non-small-cell lung cancer -- Chemotherapy of lung cancer: A global perspective of the role of ifosfamide -- Multi-targeted tyrosine kinase inhibitors for the treatment of non-small cell lung cancer: an era of individualized therapy -- Functional CT imaging techniques for the assessment of angiogenesis in lung cancer -- Updating advances on recombinant human endostatin combined with radiotherapy for non-small cell lung cancer with brain metastasis -- Conflict-Management within clinical and administrative stakeholders in medical structures --
Status quo and prospects of the translational research on lung cancer in China.